OBJECTIVE: Although a number of reports have documented a significantly increased incidence of HLA-DR15 in aplastic anemia (AA), the exact role of HLA-DR15 in the immune mechanisms of AA remains unclear. We herein clarify the difference between DRB1( *)1501 and DRB1( *)1502, the two DRB1 alleles that determine the presentation of HLA-DR15, in the pathophysiology of AA. MATERIALS AND METHODS: We investigated the relationships of the patients( *) HLA-DRB1 allele with both the presence of a small population of CD55(-)CD59(-) (PNH-type) blood cells and the response to antithymocyte globulin (ATG) plus cyclosporin (CsA) therapy in 140 Japanese AA patients. RESULTS: Of the 30 different DRB1 alleles, only DRB1( *)1501 (33.6% vs 12.8%, p(c) < 0.01) and DRB1( *)1502 (43.6% vs 24.4%, p(c) < 0.01) displayed significantly higher frequencies among the AA patients than among a control. AA patients possessing HLA-DR15 tended to be old, and especially, the frequency of DRB1( *)1502 in patients 40 years of age and older (52.4%) was markedly higher than that in those younger than 40 years old (16.2%, p(c) < 0.01). Only DRB1( *)1501 was significantly associated with the presence of a small population of PNH-type cells and it also showed a good response to ATG plus CsA therapy in a univariate analysis. A multivariate analysis showed only the presence of a small population of PNH-type cells to be a significant factor associated with a good response to the immunosuppressive therapy (p < 0.01). CONCLUSIONS: Although both DRB1( *)1501 and DRB1( *)1502 contribute to the development of AA, the methods of contribution differ between the two alleles.
OBJECTIVE: Although a number of reports have documented a significantly increased incidence of HLA-DR15 in aplastic anemia (AA), the exact role of HLA-DR15 in the immune mechanisms of AA remains unclear. We herein clarify the difference between DRB1( *)1501 and DRB1( *)1502, the two DRB1 alleles that determine the presentation of HLA-DR15, in the pathophysiology of AA. MATERIALS AND METHODS: We investigated the relationships of the patients( *) HLA-DRB1 allele with both the presence of a small population of CD55(-)CD59(-) (PNH-type) blood cells and the response to antithymocyte globulin (ATG) plus cyclosporin (CsA) therapy in 140 Japanese AA patients. RESULTS: Of the 30 different DRB1 alleles, only DRB1( *)1501 (33.6% vs 12.8%, p(c) < 0.01) and DRB1( *)1502 (43.6% vs 24.4%, p(c) < 0.01) displayed significantly higher frequencies among the AA patients than among a control. AA patients possessing HLA-DR15 tended to be old, and especially, the frequency of DRB1( *)1502 in patients 40 years of age and older (52.4%) was markedly higher than that in those younger than 40 years old (16.2%, p(c) < 0.01). Only DRB1( *)1501 was significantly associated with the presence of a small population of PNH-type cells and it also showed a good response to ATG plus CsA therapy in a univariate analysis. A multivariate analysis showed only the presence of a small population of PNH-type cells to be a significant factor associated with a good response to the immunosuppressive therapy (p < 0.01). CONCLUSIONS: Although both DRB1( *)1501 and DRB1( *)1502 contribute to the development of AA, the methods of contribution differ between the two alleles.
Authors: Eliane Maluf; Nelson Hamerschlak; Alexandre Biasi Cavalcanti; Alvaro Avezum Júnior; José Eluf-Neto; Roberto Passetto Falcão; Irene G Lorand-Metze; Daniel Goldenberg; Cézar Leite Santana; Daniela de Oliveira Werneck Rodrigues; Leny Nascimento da Motta Passos; Luis Gastão Mange Rosenfeld; Marimilia Pitta; Sandra Loggetto; Andreza A Feitosa Ribeiro; Elvira Deolinda Velloso; Andrea Tiemi Kondo; Erika Oliveira de Miranda Coelho; Maria Carolina Tostes Pintão; Hélio Moraes de Souza; José Rafael Borbolla; Ricardo Pasquini Journal: Haematologica Date: 2009-09 Impact factor: 9.941
Authors: Minoo Battiwalla; Tao Wang; Jeanette Carreras; H Joachim Deeg; Mouhab Ayas; Rajinder P S Bajwa; Biju George; Vikas Gupta; Ricardo Pasquini; Hubert Schrezenmeier; Jakob R Passweg; Kirk R Schultz; Mary Eapen Journal: Biol Blood Marrow Transplant Date: 2012-02-28 Impact factor: 5.742
Authors: Laura F Newell; Ted Gooley; John A Hansen; Derek L Stirewalt; Effie W Petersdorf; H Joachim Deeg Journal: Biol Blood Marrow Transplant Date: 2010-06-09 Impact factor: 5.742
Authors: J P McElroy; N Isobe; P A Gourraud; S J Caillier; T Matsushita; T Kohriyama; K Miyamoto; Y Nakatsuji; T Miki; S L Hauser; J R Oksenberg; J Kira Journal: Genes Immun Date: 2011-06-09 Impact factor: 2.676